Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 13Gliosarcoma 11Carcinoma, Non-Small-Cell Lung 10Uterine Cervical Neoplasms 7Adenocarcinoma of Lung 7Pancreatic Neoplasms 6Astrocytoma 6Squamous Cell Carcinoma of Head and Neck 5Rectal Neoplasms 5Lung Neoplasms 5Burkitt Lymphoma 5Breast Neoplasms 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Glioma 4Adenocarcinoma, Bronchiolo-Alveolar 4Vaginal Neoplasms 3Oropharyngeal Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

atezolizumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2talazoparib 1olaparib 1cediranib 1Radiotherapy 1Radiation 1Platinum 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Extensive Stage Lung Small Cell Carcinoma × Radiation × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡